SQZ · Sqz Biotechnologies Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $21.48M | $27.10M | $21.00M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $70.98M | $70.15M | $51.55M |
| SG&A | $26.32M | $25.72M | $20.51M |
| Total Operating Expenses | $102.16M | $95.87M | $72.06M |
| D&A | $1.50M | $1.21M | $1.34M |
| Operating Income | ($80.68M) | ($68.77M) | ($51.06M) |
| Interest Expense | - | - | - |
| Income Tax | $0 | $0 | $0 |
| Net Income | ($79.46M) | ($68.74M) | ($50.52M) |
| EPS - Basic | ($2.49) | - | - |
| EPS - Diluted | ($2.76) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $63.71M | $143.51M | $170.36M |
| Accounts Receivable | - | $3.00M | $1.89M |
| Inventory | - | - | - |
| Accounts Payable | $2.51M | $3.97M | $3.71M |
| Current Assets | $68.20M | $150.63M | $176.83M |
| Total Assets | $99.90M | $226.15M | $231.14M |
| Current Liabilities | $21.84M | $33.22M | $45.19M |
| Long-term Debt | - | - | - |
| Total Liabilities | $42.75M | $102.18M | $103.94M |
| Stockholders' Equity | $57.15M | $123.98M | $127.20M |
| Retained Earnings | ($274.97M) | ($195.51M) | ($126.77M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($83.55M) | ($82.14M) | ($43.15M) |
| Investing Cash Flow | ($488.0K) | ($613.0K) | $57.82M |
| Financing Cash Flow | $4.23M | $55.91M | $116.42M |
| CapEx | $522.0K | $613.0K | $1.18M |
| Free Cash Flow | ($84.07M) | ($82.75M) | ($44.33M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | -375.7% | -253.8% | -243.2% |
| EBITDA margin | -368.7% | -249.3% | -236.8% |
| Net margin | -370.0% | -253.7% | -240.6% |
| Free cash flow margin | -391.4% | -305.4% | -211.1% |
| FCF / Net income | 1.06 | 1.20 | 0.88 |
| R&D / Revenue | 330.5% | 258.9% | 245.5% |
| SG&A / Revenue | 122.5% | 94.9% | 97.7% |
| Effective tax rate | - | - | - |
| Return on assets | -79.5% | -30.4% | -21.9% |
| Return on equity | -139.0% | -55.4% | -39.7% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 3.12 | 4.53 | 3.91 |
| Quick ratio | 3.12 | 4.53 | 3.91 |
| Cash ratio | 2.92 | 4.32 | 3.77 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 1.75 | 1.82 | 1.82 |
| Liabilities / Assets | 0.43 | 0.45 | 0.45 |
| Efficiency | |||
| Asset turnover | 0.21 | 0.12 | 0.09 |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | 40d | 33d |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | -20.7% | 29.1% | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | -17.3% | -34.7% | - |
| Net income growth (YoY) | -15.6% | -36.1% | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | -1.6% | -86.7% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | -53.9% | -2.5% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-3.73
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing SQZ Biotechnologies Co against the 5 most active filers in the same SIC group.